The target is metastatic malignant melanoma, and the treatment is based on Ipilimumab and HF10 attenuated Herpes simplex virus. The HF10-based developments were acquired from M’s Science Corporation in 2010.
Takara Bio news release, May 1, 2014
The target is metastatic malignant melanoma, and the treatment is based on Ipilimumab and HF10 attenuated Herpes simplex virus. The HF10-based developments were acquired from M’s Science Corporation in 2010.
Takara Bio news release, May 1, 2014